The Mammostrat test, made by Clarient Diagnostic Services, is a genomic test that measures the levels of five certain genes in early-stage, hormone-receptor-positive breast cancer cells.
Research suggests the Mammostrat test eventually may be widely used to help make treatment decisions based on whether the cancer has a low or high risk of coming back (recurrence).
Knowing whether a woman has a high or low risk of early-stage breast cancer coming back might help women and their doctors decide if chemotherapy or other treatments to reduce risk after surgery are needed.
What are genomic tests?
Genomic tests analyze a sample of a cancer tumor to see how active certain genes are. The activity level of these genes affects the behavior of the cancer, including how likely it is to grow and spread. Genomic tests are used to help make decisions about whether more treatments after surgery would be beneficial.
While their names sound similar, genomic testing and genetic testing are very different.
Genetic testing is done on a sample of your blood, saliva, or other tissue and can tell if you have an abnormal change (also called a mutation) in a gene that is linked to a higher risk of breast cancer. See the Genetic Testing pages for more information.
Who’s eligible for the Mammostrat test?
Mammostrat can be used to analyze early-stage, hormone-receptor-positive breast cancers. Stage I and stage II cancers are early-stage cancers.
The Mammostrat test is performed on preserved tissue that was removed during the original biopsy or surgery.
How does the Mammostrat test work?
The Mammostrat test measures the levels of five genes in breast cancer cells. These measurements are used to calculate a risk index score. Women are assigned to a risk category (high, moderate, or low) based on their risk index score.
If you decide to have the Mammostrat test, you and your doctor will consider a number of factors when deciding whether to add chemotherapy to your treatment plan, including:
- your age
- the size of the cancer
- cancer grade
- hormone-receptor protein levels
- whether cancer cells were found in nearby lymph nodes
Insurance coverage for Mammostrat
If you’re considering the Mammostrat test, talk to your insurance company to find out if it’s covered.
Other genomic tests
There are other genomics tests used to analyze breast cancer tumors. To learn more, click on the links below.
- The Breast Cancer Index test is used to predict the risk of node-negative, hormone-receptor breast cancer coming back 5 to 10 years after diagnosis.
- The EndoPredict test is used to predict the risk of distant recurrence of early-stage, hormone-receptor-positive, HER2-negative breast cancer that is either node-negative or has up to three positive lymph nodes.
- The MammaPrint test is used to predict the risk of recurrence within 10 years after diagnosis of stage I or stage II breast cancer that is hormone-receptor-positive or hormone-receptor-negative.
- The Oncotype DX test is used to predict the risk of recurrence of early-stage, hormone-receptor-positive breast cancer, as well as how likely it is that a woman diagnosed with this type of cancer will benefit from chemotherapy after surgery. The Oncotype DX DCIS test is used to predict the risk of recurrence of DCIS and/or the risk of a new invasive cancer developing in the same breast, as well as how likely it is that a woman diagnosed with DCIS will benefit from radiation after surgery.
- The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test) is used to predict the risk of distant recurrence for postmenopausal women within 10 years of diagnosis of early-stage, hormone-receptor positive disease with up to three positive lymph nodes after 5 years of hormonal therapy.